173140-90-4 Usage
Uses
Used in Organic Synthesis:
2(1H)-Quinolinone, 5-(2R)-oxiranyl-8-(phenylmethoxy)is used as an organic synthesis intermediate due to its unique structural features. Its oxiranyl and phenylmethoxy groups can participate in various chemical reactions, such as ring-opening reactions, nucleophilic substitutions, and electrophilic aromatic substitutions, making it a versatile building block for the synthesis of more complex organic molecules.
Used in Pharmaceutical Industry:
As a pharmaceutical intermediate, 2(1H)-Quinolinone, 5-(2R)-oxiranyl-8-(phenylmethoxy)plays a crucial role in the development of new drugs. Its unique chemical properties allow it to be used as a starting material or a key intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting specific biological receptors or enzymes.
Used in Laboratory Research and Development:
2(1H)-Quinolinone, 5-(2R)-oxiranyl-8-(phenylmethoxy)is also utilized in laboratory research and development processes. Researchers can use 2(1H)-Quinolinone, 5-(2R)-oxiranyl-8-(phenylmethoxy)- to explore new reaction pathways, develop novel synthetic methods, and investigate its potential applications in various fields, such as materials science, medicinal chemistry, and chemical biology.
Used in Chemical Production Process:
In the chemical production process, 2(1H)-Quinolinone, 5-(2R)-oxiranyl-8-(phenylmethoxy)serves as an essential intermediate for the large-scale synthesis of various chemicals and pharmaceuticals. Its unique reactivity and structural features make it a valuable component in the manufacturing of specialty chemicals, fine chemicals, and active pharmaceutical ingredients.
Synthesis
A 5 liter flask equipped with a mechanical stirrer, thermometer, and refluxing condenser was charged with 8-benzyloxy-5-[(R)-(2-bromo-1-hydroxyethyl)]-carbostyriI (70gms/0.187 moles), potassium carbonate (74 gmsl 0.536 moles), acetone (3.5 liters) and water (35 ml). The resulting slurry 'was heated to reflux and maintained for 2% hours. After completion of reaction, the hot mass was filtered on hylo bed to remove inorganics. The residue was slurried in dichloromethane (200 ml) and filtered on hyflo bed. The filtrates were combined together and concentrated under vacuum completely. The residue was dissolved. in dichloromethane (500ml) and filtered on hyflo bed to remove traces of insolubles and washed with dichloromethane(100 ml). The clear filtrate was distilled completely to obtain residue. The residue was charged with methanol (70 ml), stirred and heated to 50°C for 30 minutes. The slurry obtained was cooled to 25-30°C,chilled to 0- 5°C, stirred for 1 hour. The resulting solid was isolated by filtration, washed with methanol (30ml), followed by diisopropylether (100ml) and dried under vacuum at 60-65 °C for 10-12 hours to yield 40-41 gms of 8-benzyloxy- 5-(R)-oxiranylcarbostyril.
Check Digit Verification of cas no
The CAS Registry Mumber 173140-90-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,3,1,4 and 0 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 173140-90:
(8*1)+(7*7)+(6*3)+(5*1)+(4*4)+(3*0)+(2*9)+(1*0)=114
114 % 10 = 4
So 173140-90-4 is a valid CAS Registry Number.
173140-90-4Relevant academic research and scientific papers
PROCESS FOR PREPARING ISOMERS OF CARMOTEROL
-
Page/Page column 40, (2008/12/07)
A process for preparing a compound of formula (III) comprising condensing an oxiranyl compound of formula (I) with an amine of formula (II) or a salt thereof wherein: R1 is a group selected from alkyl, aryl, allyl, alkoxy, cycloalkyl, heterocyclic, alkenyl, benzocycloalkyl, aralkyl, haloarylalkyl, heteroaralkyl, haloalkyl, alkoxyaralkyl, substituted silyl and benzyl; and R2 is hydrogen, optionally substituted silyl or optionally substituted benzyl. Formula (I), (II) and (III): There is also described a process for preparing (R,R)-carmoterol from compound (III).
ORGANIC COMPOUNDS
-
Page/Page column 36, (2008/06/13)
A process for preparing 8-substituted oxy-5-((R)-2-halo-l-hydroxy-ethyl)-(1 H)-quinolin-2-ones or acceptable solvates thereof. The process involves reacting a 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one with a reducing agent in the presence of a chiral agent and a base to form a 8-(substituted oxy)-5-((R)-2-halo-l-hydroxy-ethyl)-(1H)-quinolin-2-one, said chiral agent having a formula (I) or (II), wherein M, L, X, R1, R2 and R3 have the meanings as indicated in the specification.
A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES
-
Page 30-31, (2008/06/13)
The invention relates to a process for preparing 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-ones. The process involves (i) reacting (a) 8-hydroxy-(1H)-quinolin-2-one with an acylating agent and a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one; or (b) 8-hydroxy-(lH)-quinolin-2-one with an acylating agent to form 8-acetoxy-(lH)-quinolin-2-one, and treating, in-situ, the 8-acetoxy-(1H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one; or (c) 8-acetoxy-(1H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(lH)-quinolin-2-one; (ii) reacting the 5-acetyl-8-hydroxy-(1H)-quinolin-2-one prepared in Step (i) with a compound having the Formula RL in the presence of a base and a solvent to form 5-acetyl-8-substituted oxy-(1H)-quinolin-2-one, wherein R is a protecting group and L is a leaving group; and (iii) reacting the 5-acetyl-8-substituted oxy-(1H)-quinolin-2-one with a halogenating agent in the presence of a solvent to form a 5-(α-haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one.
PROCESS FOR PREPARING 5-'(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMINO)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST
-
Page/Page column 22, (2008/06/13)
A process for preparing 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1H)-quinolin-2-one salt. The process involves forming an acid salt of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-substituted oxy-(1 H)-quinolin-2-one (V); and converting the acid salt to a salt of 5-[(R)-2-(5, 6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1H)-quinolin-2-one (VI) without isolating the free base of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1H)-quinolin-2-one. Formula (A); (V): R = a protecting group, (VI): R = H.